Ravuconazole self-emulsifying delivery system: in vitro activity against Trypanosoma cruzi amastigotes and in vivo toxicity

References

• ChagasCNova tripanozomiase humana. Estudo sobre a morfologia e o ciclo evolutivo do Schizotrypanum cruzi. n. gen., n. sp. agente etiológico de nova entidade mórbida do homemMem Inst Oswaldo Cruz19091159218
   Google Scholar
• World Health Organization [webpage on the Internet]Chagas disease (American trypanosomiasis) Fact sheet No 340 [updated March, 2016] Available from: http://www.who.int/mediacentre/factsheets/fs340/en/Accessed April 10, 2017
   Google Scholar
• CouraJRCastroSLA critical review on Chagas disease chemotherapyMem Inst Oswaldo Cruz200297132411992141
   PubMed Web of Science ®Google Scholar
• Pinto DiasJCThe treatment of Chagas disease (South American trypanosomiasis)Ann Int Med20061441077277416702594
   PubMedGoogle Scholar
• FilardiLSBrenerZSusceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas diseaseTrans R Soc Trop Med Hyg19878157557593130683
   PubMed Web of Science ®Google Scholar
• CançadoJRLong term evaluation of etiological treatment of Chagas disease with benznidazoleRev Inst Med Trop São Paulo2002441293711896410
   PubMedGoogle Scholar
• GuedesPMMFiettoJLRLanaMBahiaMTAdvances in Chagas disease chemotherapyAnti Infect Agents Med Chem20065175186
   Google Scholar
• UrbinaJASpecific chemotherapy of Chagas disease: relevance, current limitations and new approachesActa Trop20101151–2556819900395
   PubMed Web of Science ®Google Scholar
• CastroJAde MeccaMMBartelLCToxic side effects of drugs used to treat Chagas disease (American trypanosomiasis)Hum Exp Toxicol200625847147916937919
   PubMed Web of Science ®Google Scholar
• MuñozMJMurciaLSegoviaMThe urgent need to develop new drugs and tools for the treatment of Chagas diseaseExpert Rev Anti Infect Ther2011915721171870
   PubMed Web of Science ®Google Scholar
• BilbeGOvercoming neglect of kinetoplastid diseasesScience2015348623897497626023124
   PubMed Web of Science ®Google Scholar
• ChoiJYPodustLMRoushWRDrug strategies targeting CYP51 in neglected tropical diseasesChem Rev201411422112421127125337991
   PubMedGoogle Scholar
• UrbinaJADocampoRSpecific chemotherapy of Chagas disease: controversies and advancesTrends Parasitol2003191149550114580960
   PubMed Web of Science ®Google Scholar
• UrbinaJAPayaresGSanojaCLiraRRomanhaAJIn vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas diseaseInt J Antimicrob Agents2003211273812507835
   PubMed Web of Science ®Google Scholar
• DinizLFCaldasISGuedesPMMEffects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruziAntimicrob Agents Chemother20105472979298620404124
   PubMed Web of Science ®Google Scholar
• CaoXSunZCaoYDesign, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubilityJ Med Chem20145793687370624564525
   PubMedGoogle Scholar
• LentzKAQuitkoMMorganDGGraceJEJrGleasonCMarathePHDevelopment and validation of a preclinical food effect modelJ Pharm Sci200796245947217075867
   PubMedGoogle Scholar
• UedaYMatiskellaJDGolikJPhosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological propertiesBioorg Med Chem Lett200313213669367214552754
   PubMedGoogle Scholar
• MüllertzAOgbonnaARenaSRadesTNew perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugsJ Pharm Pharmacol201062111622163621039546
   PubMed Web of Science ®Google Scholar
• PoutonCWPorterCJFormulation of lipid-based delivery systems for oral administration: materials, methods and strategiesAdv Drug Deliv Rev200860662563718068260
   PubMed Web of Science ®Google Scholar
• DateAADesaiNDixitRNagarsenkerMSelf-nanoemulsifying drug delivery systemsNanomedicine20105101595161621143036
   PubMed Web of Science ®Google Scholar
• DriscollCMLipid-based formulations for intestinal lymphatic deliveryEur J Pharm Sci200215540541512036717
   PubMedGoogle Scholar
• De MelloCGCBranquinhoRTOliveiraMTEfficacy of lychnopholide polymeric nanocapsules after oral and intravenous administration in murine experimental Chagas diseaseAntimicrob Agents Chemother20166095215522227324760
   PubMedGoogle Scholar
• BranquinhoRTMosqueiraVCFOliveira-SilvaJCVDSimões- SilvaMRSaúde-GuimarãesDADe LanaMSesquiterpene lactone in nanostructured parenteral dosage form is efficacious in experimental Chagas diseaseAntimicrob Agents Chemother20145842067207524449777
   PubMedGoogle Scholar
• BranquinhoRTRoyJFarahCBiodegradable polymeric nanocapsules prevent cardiotoxicity of anti-trypanosomal lychnopholideSci Rep201774499828349937
   PubMedGoogle Scholar
• ZingalesBAndradeSGBrionesMRSSecond Satellite MeetingA new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVIMem Inst Oswaldo Cruz200910471051105420027478
   PubMed Web of Science ®Google Scholar
• GrollAHMickieneDPetraitisVCompartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbitsJ Antimicrob Chemother200556589990716172108
   PubMed Web of Science ®Google Scholar
• Cendejas-BuenoERodríguez-TudelaJLCuenca-EstrellaMGómez-LópezADevelopment and validation of a fast HPLC/photodiode array detection method for the measurement of voriconazole in human serum samples. A reference laboratory experienceEnferm Infecc Microbiol Clin2013311232822776376
   PubMed Web of Science ®Google Scholar
• RoweRCSheskeyPJQuinnMEHandbook of Pharmaceutical Excipients6th edLondonRoyal Pharmaceutical Society of Great Britain2009
   Google Scholar
• GaliaENicolaidesEHörterDLöbenbergRReppasCDressmanJBEvaluation of various dissolution media for predicting in vivo performance of Class I and Class II drugsPharm Res19981556987059619777
   PubMed Web of Science ®Google Scholar
• SoundararajanRSasakiKGodfreyLDirect in vivo evidence on the mechanism by which nanoparticles facilitate the absorption of a water insoluble, P-gp substrateInt J Pharm2016514112113227863655
   PubMed Web of Science ®Google Scholar
• OliveiraLTGarciaGMKanoEKTedescoACMosqueiraVCFHPLC-FLD methods to quantify chloroaluminum phthalocyanine in nanoparticles, plasma and tissue: application in pharmacokinetic and biodistribution studiesJ Pharm Biomed Anal2011561707721596512
   PubMedGoogle Scholar
• DinizLFUrbinaJAAndradeIMBenznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatmentsPLoS Negl Trop Dis201378e236723967360
   PubMedGoogle Scholar
• RomanhaAJCastroSLSoeiroMNIn vitro and in vivo experimental models for drug screening and development for Chagas diseaseMem Inst Oswaldo Cruz2010105223323820428688
   PubMed Web of Science ®Google Scholar
• DelongeasJLConchardGVBeamonteAAssessment of labrasol/labrafil/transcutol (4/4/2, v/v/v) as a non-clinical vehicle for poorly water-soluble compounds after 4-week oral toxicity study in Wistar ratsRegul Toxicol Pharmacol2010572–328429020347907
   PubMed Web of Science ®Google Scholar
• GhaichaLLeblancRMVillamagnaFChattopadhyayAKMonolayers of mixed surfactants at the oil-water interface, hydrophobic interactions, and stability of water-in-oil emulsionsLangmuir1995112585590
   Web of Science ®Google Scholar
• PoutonCWFormulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification systemEur J Pharm Sci2006293–427828716815001
   PubMed Web of Science ®Google Scholar
• PorterCJPoutonCWCuineJFCharmanWNEnhancing intestinal drug solubilisation using lipid-based delivery systemsAdv Drug Deliv Rev200860667369118155801
   PubMed Web of Science ®Google Scholar
• O’BrienRDFats and Oils: Formulating and Processing for Applications3th edBoca Raton, FLCRC Press2008
   Google Scholar
• ChudasamaAPatelVNivsarkarMVasuKShishooCRole of lipid-based excipients and their composition on the bioavailability of antirretroviral self-emulsifying formulationsDrug Deliv201522453154024601856
   PubMed Web of Science ®Google Scholar
• JummaMMüllerBWInfluence of the non-ionic surfactant PEG-660-12-hydroxy stearate on the surface properties of phospholipid monolayers and their effect on lipid emulsion stabilityColloid Polym Sci19992774347353
   Google Scholar
• BrewerAKStriegelAMParticle size characterization by quadruple-detector hydrodynamic chromatographyAnal Bioanal Chem2009393129530218762925
   PubMed Web of Science ®Google Scholar
• StauchOSchubertRSavinGBurchardWStructure of artificial cytoskeleton containing liposomes in aqueous solution studied by static and dynamic light scatteringBiomacromolecules20023356557812005530
   PubMedGoogle Scholar
• UjhelyiaZFenyvesiaFVáradiaJEvaluation of cytotoxicity of surfactants used in self-micro emulsifying drug delivery systems and their effects on paracellular transport in Caco-2 cell monolayerEur J Pharm Sci201247356457322841998
   PubMedGoogle Scholar
• KawakamiKYoshikawaTMorotoYMicroemulsion formulation for enhanced absorption of poorly soluble drugs. I. Prescription designJ Control Release2002811–2657411992679
   PubMed Web of Science ®Google Scholar
• KimHJYoonKAHahnMParkESChiSCPreparation and in vitro evaluation of self-microemulsifying drug delivery systems containing idebenoneDrug Dev Ind Pharm200026552352910789064
   PubMed Web of Science ®Google Scholar
• MosqueiraVCFLegrandPPinto-AlphandaryHPuisieuxFBarrattGPoly (D,L-lactide) nanocapsules prepared by solvent displacement process: influence of composition on physico-chemical and structural propertiesJ Pharm Sci200089561462610756327
   PubMedGoogle Scholar
• HörterDDressmanJBInfluence of physicochemical properties on dissolution of drugs in the gastrointestinal tractAdv Drug Deliv Rev199725314
   Web of Science ®Google Scholar
• ElnaggarYSREl-MassikMAAbdallahOYSelf-nanoemulsifying drug delivery systems of tamoxifen citrate: design and optimizationInt J Pharm20093801–213314119635537
   PubMed Web of Science ®Google Scholar
• ShaXYanGWuYLiJFangXEffect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cellsEur J Pharm Sci200524547748615784337
   PubMed Web of Science ®Google Scholar
• CornaireGWoodleyJHermannPCloarecAArellanoCHouinGImpact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivoInt J Pharm2004278111913115158955
   PubMed Web of Science ®Google Scholar
• GursoyRNBenitaSSelf-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugsBiomed Pharmacother200458317318215082340
   PubMed Web of Science ®Google Scholar
• BuddenRKühlGBahlsenJExperiments on the toxic, sedative and muscle relaxant potency of various drug solvents in micePharmacol Ther B197951–3467474493327
   PubMedGoogle Scholar
• StrickleyRGSolubilizing excipients in oral and injectable formulationsPharm Res200421220123015032302
   PubMed Web of Science ®Google Scholar
• JumaaMMüllerBWLipid emulsions as a novel system to reduce the hemolytic activity of lytic agents: mechanism of the protective effectEur J Pharm Sci20009328529010594386
   PubMedGoogle Scholar